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Introduction
Erectile dysfunction (ED) is highly prevalent and by cur-
rent estimated, 30 million men in US and 150 million
men worldwide are affected and occurs in 19–64% of
men aged 40–80 years, both developing and industrialized
countries (Benet et al., 1995). Although ED is a multifac-
torial process, vascular disease of the penile arteries is an
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Summary
The plasma concentration of asymmetrical dimethylarginine (ADMA), an inhibi-
tor of nitric oxide synthase, has been linked to endothelial dysfunction. We
investigated the relation between ADMA, symmetric dimethylarginine (SDMA)
and L-arginine concentrations and erectile dysfunction. We compared plasma
levels of ADMA, SDMA and L-arginine in 61 men in good health with erectile
dysfunction of arteriogenic and non-arteriogenic origin. Diagnosis of erectile
dysfunction was based on the International Index of Erectile Function Score and
its aetiology was classified with penile echo-colour-Doppler in basal condition
and after intracavernous injection of prostaglandin E1. The ADMA and SDMA
concentrations were significantly higher in men with arteriogenic erectile dys-
function compared with those with erectile dysfunction of non-arteriogenic ori-
gin (p < 0.05) and the concentrations in both subgroups were significantly
higher than in controls (p < 0.001). There was a negative correlation between
ADMA and International Index of Erectile Function Score only in arteriogenic
erectile dysfunction subgroup. L-arginine did not differ significantly neither
between the two erectile dysfunction subgroups (p > 0.05) nor between each of
the two erectile dysfunction subgroups and controls (p > 0.05). The L-argi-
nine ⁄ADMA and the L-arginine ⁄ SDMA ratios in arteriogenic erectile dysfunc-
tion subgroups were significantly lower than both in controls (p < 0.05) and in
non-arteriogenic erectile dysfunction patients (p < 0.05); the two ratios in non-
arteriogenic erectile dysfunction patients did not differ from those in the controls
(p > 0.05). We conclude that ADMA and SDMA concentrations are significantly
higher and L-arginine ⁄ADMA ratio lower in patients who have arteriogenic erec-
tile dysfunction compared with both patients with non-arteriogenic erectile dys-
function and controls. The negative correlation between ADMA and severity of
erectile dysfunction is present only in patients with arteriogenic erectile dysfunc-
tion. This study supports the importance to always distinguish arteriogenic from
non-arteriogenic erectile dysfunction patients to study the complicate erectogen-
ic mechanisms that lead to erectile dysfunction and also to provide potential
therapeutic agents for patients with arteriogenic erectile dysfunction.
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important cause of ED accounting for up to 80% of cases
(Kendirci et al., 2007). It has been suggested that endo-
thelial dysfunction is linked to ED as both share a depen-
dence on a common pathway through the nitric oxide
(NO) release (Burchardt et al., 2001; Hashimoto et al.,
2000; Widlansky et al., 2003; De Angelis et al., 2001). NO
is the major endothelium-derived relaxing factor, playing
a critical role in the maintenance of vascular tone (Palmer
et al.,1988). Penile tumescence and erection is critically
reliant on the NO release by both cavernosal nerve termi-
nals and endothelial cells (Sa`enz de Tajada et al., 2004).
NO is formed from the precursor amino acid, L-arginine,
by enzymatic action of nitric oxide synthase (NOS). NO
production may be regulated by endogenous NOS com-
petitive inhibitor asymmetric dimethylarginine (ADMA),
a L-arginine analogous. The ADMA levels in plasma are a
balance between breakdown of proteins containing methy-
lated arginine, renal excretion and the activity of hepatic
dimethylarginine dimethylaminohydrolase (DDAH). The
L-arginine analogous identified to day, include monome-
thylarginine (NMMA), symmetric dimethylarginine
(SDMA) and ADMA. It was postulated that ADMA, which
was identified as circulating in human plasma at a concen-
tration 10 times greater than that of naturally occurring
NMMA, might act as an important endogenous regulator
of the NO pathway (Vallance et al., 1992).
In view of the apparent role of NO as the key chemical
element necessary for penile erection, investigators have
begun to explore the incidence of ED in conditions asso-
ciated to a deregulated ADMA and ⁄or SDMA metabolism
as diabetes mellitus, hypercholesterolaemia, renal failure,
hypogonadism, ageing and irradiation (Schiel et al., 2003;
Maas et al., 2005; Elesberg et al., 2006; Wierzbicki et al.,
2006; Kielstein et al., 2005; Lugg et al., 1995; Garban et
al., 1995; Carrier et al., 1995). Moreover, over the past
decade the interference of these substrates with cardiovas-
cular function has received increasing interest and several
lines of evidence suggest that ADMA is involved in the
pathogenesis of cardiovascular diseases (Valkonen et al.,
2001; Cooke et al., 2004).
As ED may be an early marker for the presence of sub-
clinical atherosclerosis (Solomon et al., 2003) we studied
the plasma concentrations of L-arginine, ADMA and
SDMA in men with arteriogenic and non-arteriogenic
ED, to assess the differences between the two ED sub-
groups and the healthy subjects, independently by the
presence of clinical or subclinical atherosclerosis.
Materials and methods
Investigation protocol
In our centre, patients complaining of ED are currently
investigated by careful history-taking and clinical andro-
logical examination; then, a few days later, by a panel of
examinations, including blood tests, complete blood pic-
ture, haemoglobin, glycated haemoglobin, glycaemia,
urea, creatinine, PCR, total and HDL cholesterol, triglyce-
rides, transaminases, testosterone, prolactin, 17-b-estra-
diol, urine analysis and 24-h urinary albumin excretion
(microalbuminuria), the International Index of Erectile
Function questionnaire (IIEF) and echo-colour-Doppler
of both cavernous arteries.
The IIEF questionnaire (Rosen et al., 1999) is a vali-
dated, self-administered tool (Rosen et al., 1999; Rosen et
al., 1997), but we only evaluated the answers to the first
five (erectile response dominium) of the 15 questions
(IIEF–15, 1–5). Possible scores for the IIEF-5 range from
5 to 25, scores of 22–25 indicate normal erectile function
whereas scores of 21 or below indicate ED (Rosen et al.,
1999 Rosen et al., 1999).
Penile echo-colour-Doppler was performed in basal
conditions and after intracavernous injection of 10 lg
prostaglandin E1 (PgE1) (Aversa et al. 2005), and the
peak systolic velocity (PSV) and end-diastolic velocity
(EDV) were recorded at 5, 10, 15, 20 and 25 min after
the injection in the proximal portion of the penis.
Patients were classified as ‘non-arteriogenic’ when their
PSV was ‡35 cm ⁄ sec, or £35 cm ⁄ sec, but >25 cm ⁄ sec
with concomitant EDV £ 0 cm ⁄ sec, and ‘arteriogenic’
when their PSV was £20 cm ⁄ sec (Barassi A et al., 2009;
Barassi et al., 2010). The erection quality was estimated
20 min after each injection. If a patient appeared stressed,
he was given a second injection of the same dose of PgE1
and all measurements were repeated. From 30 to 60 min
after the penile echo-colour-Doppler, participants were
placed in a supine position and blood samples were
drawn from a cubital vein into EDTA tubes. Samples
were centrifuged at 4000 g for 10 min. The serum was
separated and stored at )80 C until analysis.
Patients and control group
Of a series of 590 filed ED cases studied in the period
October 2008–August 2010, we randomly selected 29 arte-
riogenic ED patients (ED AR) and 32 non-arteriogenic
ED patients (ED NON-AR), according to our exclusion
criteria for this study, for a total of 61 cases (median age
48.3 years, range 36–53) with a history of at least
3 months, but not more than 1 year of ED. General
exclusion criteria were: age below 30 years, congestive
heart failure, diabetes, renal failure, anaemia, acute infec-
tion or rheumatic disease, evidence from the patient’s
clinical history of coronary artery disease, hypertension
(>140 ⁄ 90 mm Hg in three consecutive recondings at
rest), malignancy, systemic inflammatory disease, hepat-
opathies or arrhythmias, current smoking (Tostes et al.,
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2008) and vitamins supplementation. Our patients did
not take any therapy.
The 30 healthy controls were all blood donors (median
age 45.1 years, range 34–49), and, according to their
answers to the first five IIEF-15 questions (erectile
response domain), did not suffer from ED. Both healthy
controls and the patients of the two ED subgroups
declared to develop a normal physical activity.
In accordance with the Declaration of Helsinki II, the
design of the study was explained thoroughly to all the
participants, and informed consent was obtained for all
the test of the study from all ED patients and controls,
and for administering the IIEF-15 test to controls. In par-
ticular, it was explained to the participants that no addi-
tional blood needed for this study.
Assays
From 60 to 90 min before the penile echo-color-Doppler,
participants to the study were placed in a supine position
and blood samples were drawn from a cubital vein into
EDTA tubes. HbA1c was measured using a high perfor-
mance liquid chromatography (HPLC) method (Bio-
Rad). Plasma glucose, creatinine, urea, total cholesterol,
HDL-cholesterol, triglycerides, hsCRP, ALT, AST, prolac-
tin, testosterone and 17-b-estradiol were analysed with
commercially available kits using Modular EVO (Roche).
Plasma LDL-cholesterol was calculated with the use of
Friedewald’s formula. Urinary microalbumin concentra-
tion was measured in duplicate in the morning samples
on a Behring Nephelometer II analyser (Siemens).
Plasma concentrations of ADMA, SDMA and L-argi-
nine were determined by the method described by Paroni
et al. (Paroni et al., 2005). Briefly, after adding L-hom-
oarginine as internal standard, 100 lL of plasma samples
were submitted to solid phase extraction on SCX car-
tridges (Phenomenex STRATA SCX, 55 lm, 70 A,
100 mg ⁄ 1 mL). Following three washing steps with TCA
2%, phosphate buffer pH 8.0 and methanol, respectively,
cationic amino acids (ADMA, SDMA, homoarginine and
L-arginine) were eluted with 1 mL of a methanol : water
solution (70 : 30, v : v) containing 2% triethylamine. The
eluate was evaporated to dryness under a gentle nitrogen
stream and the residue was resuspendend in water. This
was followed by online ortho-phthaldialdehyde derivatisa-
tion, HPLC separation (Ultrasphere Beckman ODS,
250 · 4.6 mm, 5 lm) and fluorimetric detection (kecc
340 nm, kem 455 nm). The liquid chromatographic sys-
tem included an Agilent 1200 Series Rapid Resolution
chromatograph equipped with binary pump SL, thermo-
statted column compartment SL, high performance auto-
sampler SL plus and a 1260 Infinity Fluorescence
Detector. Within-assay and between-assay variations for
all the analytes were <3.0% and <6.0%, respectively; the
detection limit of the assay was 1.5 pmol injected at a sig-
nal-to-noise ratio of 3 : 1. The total run time was 32 min.
Statistical analysis
All the variables were expressed as median and range (or
25% and 75% percentiles). Normal distribution of the
data was tested by the Kolmogorov–Smirnov test. The
significance of differences between controls, ED AR and
ED non-AR was assessed by the non-parametric test
Mann–Whitney Rank sum test. Spearman correlation was
used to assess the strength of association between vari-
ables. Probabilities £0.05 were considered to be statisti-
cally significant. All analyses were performed using the
statistical software package Sigma Stat (Statistical Analysis
System, version 3.0) (Jandel Scientific GmbH, Erkrath,
Germany).
Results
Of the 61 men included in the study, 29 (47.5%) were
classified as having ED AR and 32 (52.5%) as having ED
NON-AR. Clinical and laboratory features of 30 controls
and 61 patients with ED are presented in Table 1. In ED
AR (median age 49.2 years, range 42–52) and ED NON-
AR (median age 47.5 years, range 36–53) the median of
IIEF values were 10.5 (range 5–19) and 12.8 (range 7–20)
respectively. There were no significant differences between
the two ED subgroups (p > 0.05). There were no differ-
ences neither between ED patients and controls nor
between the two ED subgroups regarding all the labora-
tory tests (p > 0.05). Hormonal status of all patients was
in the normal range (Table 1).
The ADMA concentration (median and range in
lmol ⁄L) in ED AR [0.682 (0.536–0.811)] and in ED
NON-AR [0.554 (0.492–0.722)] was significantly higher
(p = 0.003) compared with controls [0.445 (0.380 –
0.570)]; in ED AR it was also significantly higher
(p = 0.038) than in ED NON-AR.
The SDMA concentration in ED AR [0.746 (0.613–
0.808)] and in ED NON-AR [0.592 (0.528–0.751)] was
significantly higher (p = 0.003 and p £ 0.001 respectively)
compared with controls [0.465 (0.425–0.529)]; in ED AR
it was also significantly higher (p = 0.030) than in ED
NON-AR. The results are reported in Fig. 1.
Spearman correlation analysis demonstrated a negative
correlation between serum ADMA levels and IIEF score
that reached the significance in ED AR (r = )0.396;
p < 0.01) but without reaching the significance in ED
NON-AR (r = )0.03; p < 0.20).
The L-arginine plasma concentration (median and
range in lmol ⁄L) did not differ significantly (p > 0.05)
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neither between ED AR [54.10 (46.67–65.57)] or between
ED NON-AR [53.80 (40.23–62.30)] and controls [47.15
(36.20–60.50)] nor between the two ED subgroups.
The L-arginine ⁄ADMA ratio [66.50 (52.17–90.95)] and
L-arginine ⁄ SDMA ratio [72.10 (59.37–82.7)] in ED AR
were significantly lower (p = 0.002) than in controls [100
(85.5–136.5) and 105.5 (78–144)] and than in ED NON-
AR [87.70 (82.40–116.70) p = 0.004 and 82.90 (78–114)
p = 0.029]; the two rations in ED NON-AR did not differ
(p > 0.05) from the controls (Fig. 2).
Discussion and conclusions
Cells regulate NO homeostasis by different mechanisms.
eNOS (type 3) and nNOS (type 1) are constitutively
expressed low output enzymes whose ezymatic activity
depends on Ca2 + levels, protein myristilation, phosphor-
ylation and protein ⁄protein interactions. By contrast,
iNOS (type 2) is an inducible NO synthase not normally
expressed in resting cells, and upon stimulation by vari-
ous cytokines or bacterial lipopolysaccharide its transcrip-
tion can be induced within several hours. The discovery
of ADMA and demonstration of in vivo and in vitro
effects on inhibiting NO synthesis has led to a large body
of work attempting to discover its role in a wide range of
different clinical conditions which share endothelial
dysfunction as a common feature. After proteolysis of
methylated proteins, ADMA is released within cells where
can concur to regulate excessive iNOS activity, as well as
the other NOS isoforms by competing with the NOS nat-
ural substrate arginine (Vallance et al., 1992; Ueda et al.,
2003). The local concentrations of substrate and inhibi-
tors, i.e. the L-arginine ⁄ADMA concentration ratio, may
be therefore an important factor, although not the only,
in the pathogenesis of ED in various disease states. Pre-
sumably, the state of activation or inhibition of NOS will
depend on ADMA exported from the site of origin by
cationic amino acid transporter, the same used by L-argi-
nine (CAT) (Baylis 2006; Welch et al., 1997). The major-
ity of ADMA is metabolized by the enzyme DDAH to
yield citrulline and dimethyl-amine (Achan et al., 2003;
Tsuji et al., 1986; Palm et al., 2007). Intracellular ADMA
that escapes metabolism by DDAH, besides to inhibit
NOS, may also reduce NO generation by competing with
L-arginine for cellular uptake by CAT transporter. Thus,
ADMA not only blocks NOS activity but also limits the
cellular uptake of L-arginine, thereby contributing to oxi-
dative stress that further inhibits NO biogenesis (Bo¨gerk
et al., 2009). SDMA, in contrast, has no direct effect on
NOS. However, it may still be important by competing
with L-arginine for transport across the CAT (Closs et al.,
1997; Bode- Bo¨ger et al., 2006). Thus, also SDMA may
indirectly limit NO generation.
The populations studied, ED and controls, were homo-
geneous with similar patterns of metabolic and inflamma-
tory variables. It is generally accepted that ED has been
Table 1 Clinical and laboratory features of controls and patients with erectile dysfunction
Controls (n = 30) ED (n = 61) ED-AR (n = 29) ED-NON AR (n = 32)
Age (years) 45.1 (34–49) 48.3 (36–53) 49.2 (42–52) 47.5 (36–53)
Systolic pressure (mmHg) 125 (118–137) 128 (116–138) 130 (118–138) 127 (116–135)
Diastolic pressure (mmHg) 82 (75–86) 85 (72–88) 87 (80–88) 83 (72–86)
Heart rate (bpm) 72 (65–81) 75 (63–88) 77 (65–88) 73 (63–85)
Body mass index (kg ⁄m2) 26.2 (22.3–27.4) 27.3 (21.8–28.2) 27.5 (22.5–28.2) 26.8 (21.8–27.7)
Diuresis (L) 1.6 (1.3–2.0) 1.7 (1.2–2.1) 1.8 (1.4–2.3) 1.5 (1.2–1.99)
Microalbuminuria (mg ⁄ L) 11 (11–14) 11 (11–13) 11 (11–13) 11 (11–12)
HbA1c (%) 4.9 (4.7–5.2) 5.2 (5.0–5.4) 5.2 (4.9–5.3) 5.2 (5.0–5.4)
Glucose (mg ⁄ dL) 90.2 (80–96) 94.1 (85–99) 95.9 (89–102) 93.3 (84–95)
hs-PCR (mg ⁄ L) 0.9 (0.5–1.9) 1.1 (0.6–2.1) 1.3 (0.7–2.5) 0.8 (0.5–1.5)
17-b-estradiol (pg ⁄mL) 26 (22.5–27.8) 25.5 (22.5–31.4) 25.8 (20.0–33.5) 25.5 (23.8–30.5)
Prolactin (ng ⁄mL) 6.9 (5.8–8.5) 7.5 (6.1–9.1) 7.4 (6.6–8.4) 7.9 (6.0–9.9)
Testosterone (ng ⁄mL) 4.9 (3.9–5.3) 4.6 (3.8–5.1) 4.5 (3.8–4.8) 4.7 (3.8–5.5)
Creatinine (mg ⁄ dL) 0.81 (0.75–0.88) 0.85 (0.79–1.00) 0.82 (0.73–0.89) 0.85 (0.78–0.92)
Urea (mg ⁄ dL) 37 (32–45) 38 (33–45) 37 (32–46) 39 (34–45)
ALT (U ⁄ L) 25 (20–32) 26 (19–39) 29 (22–43) 26 (19–34)
AST (U ⁄ L) 28 (20–34) 27 (22–31) 29 (23–32) 26 (22–31)
Total cholesterol (mg ⁄ dL) 196 (159–220) 208 (177–226) 198 (175–213) 211 (186–227)
Triglycerides (mg ⁄ dL) 118 (92–140) 112 (89–144) 116 (94–161) 112 (84–131)
HDL cholesterol (mg ⁄ dL) 53 (45–63) 55 (46–64) 52 (46–61) 57 (50–64)
IIEF-5 score 23 (22–25) 11.6 (5–20)a 10.5 (5–19)a 12.8 (7–20)a
Values are reported as median and range.
ap < 0.001 vs. Controls.
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associated with advanced artheriosclerotic CAD (Solomon
et al., 2003; Feldman et al., 2000; Takiuchi et al., 2004):
then, the subjects with clinical history of CAD and ⁄or
with atherosclerotic risk factors were excluded from the
study. As ADMA has been associated with characteristics
of the metabolic syndrome only subjects without those
characteristics were included in our study.
In this study of well-characterized patients, in particu-
lar as regards the penile arteriogenic and non-arteriogenic
aetiology of ED, we found a significant increase of ADMA
and SDMA concentrations in both the ED subgroups
compared with healthy controls and in ED AR compared
with ED NON-AR. Our findings confirm recent data of
Ioakeimidis et al. that found ADMA levels significantly
higher in ED AR than in ED NON-AR patients with an
independent inverse association between ADMA and PSV
(Ioakeimidis et al. 2011).
Although elevated ADMA levels in patients with renal
failure could be attributed, at least in part, to reduced
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Figure 1 Plasma ADMA (a), SDMA (b) and L-arginine (c) concentra-
tions in men with arterogenic (ED AR), non-arterogenic (ED NON-AR)
erectile dysfunction and in controls. *p = 0.003 vs. controls;
#p < 0.001 vs. controls; $p = 0.038 vs. ED NON-AR; &p = 0.030 vs.
ED NON-AR. Controls did not received intracavernous injection of
PgE1. The boundary of the box closest to zero indicates the 25th per-
centile, the line within the box marks the median, and the boundary
of the box farthest from zero indicates the 75th percentile. Whiskers
(error bars) above and below the box indicate the 90th and 10th per-
centiles. Black circles are the outlying points.
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Figure 2 L-arginine ⁄ADMA ratio (a) and L-arginine ⁄ SDMA ratio (b) in
men with arterogenic (ED AR), non-arterogenic (ED NON-AR) erectile
dysfunction and in controls. §p = 0.002 vs. controls; &p = 0.040 vs.
ED NON-AR; £p = 0.029 vs. ED NON-AR. Controls did not receive
intracavernous injection of PgE1.
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renal excretion, the precise cause of elevated ADMA levels
in ED has not been identified yet. One cause could be a
reduced activity of DDHA, highly expressed in the liver
(Nijveldt et al., 2003), whose activity may be inhibited by
a large series of traditional (hypercholesterolaemia, diabe-
tes, smoking), non-traditional (hyperhomocysteinaemia,
inflammation, oestrogen deficiency, insulin resistence,
hypothyroidism) risk factors and finally by oxidative
stress. A fairly recent study showed that plasma reactive
oxygen metabolite (ROS) concentrations were higher and
plasma total antioxidant status (TAS) was lower in ED
AR patients in comparison with ED NON-AR patients
and in controls (Barassi et al., 2009). Furthermore,
through uncoupling of NOS, increased production of
superoxide could further impair DDAH, leading to a per-
petuating increase in ADMA concentration (Sydow et al.,
2003).
There were no significant differences neither between
ED patients and controls nor between the two ED sub-
groups regarding L-arginine concentration. L-argi-
nine ⁄ADMA ratio and L-arginine ⁄ SDMA ratio were
significantly lower in ED AR in comparison with those in
the controls and in ED NON-AR. In ED NON-AR, the
two ratios were not different from those in the controls.
A low L-arginine ⁄ADMA ratio (i.e. the ratio of NOS sub-
strate and its endogenous inhibitor concentrations) is
compatible with ADMA acting as a competitive inhibitor
of NOS, resulting in a reduced NO synthesis. It is more
difficult to explain the increased level of SDMA and the
decreased L-arginine ⁄ SDMA ratio in ED patients. In fact,
the role of SDMA in these pathologies is not yet com-
pletely clear. Nevertheless, the decrease of the ratio only
in ED AR can contribute to limit NO generation by
reducing the availability of L-arginine, the NOS substrate.
The HPLC method used for quantification is character-
ized by a very low imprecision, allowing reliable determi-
nation also in the presence of small concentration
differences between groups. Nevertheless, we found near
borderline significant differences in ADMA and L-argi-
nine ⁄ADMA levels between AR and NON-AR patients;
then, from a diagnostic standpoint it needs caution in
discerning between AR and NON-AR patients from levels
near the limit of reference ranges. The concentrations of
both ADMA and SDMA are tightly controlled in health,
with intraindividual variations (CVi) of 7.4% and 5.8%
respectively (Blackwell et al., 2007). Based on a desirable
imprecision of no more than 0.5 times CVi (Fraser et al.,
1999), our method meet this goal. In addition, both the
generation of NO and the formation of the L-arginine
analogous, by the sequence of protein methylation and
proteolysis, are intracellular processes. ADMA and SDMA
in plasma probably originate from cellular spillover. A
limited increase in the plasma concentration may thus
reflect a much larger increase of their intracellular con-
centration, which may be sufficient to substantially inhibit
NO production. In fact, cells can concentrate L-arginine
analogous up to 5–10 times than that in plasma.
This study supports the hypothesis that elevated
ADMA and normal-low or low L-arginine levels may con-
tribute, either directly or through NOS uncoupling, to
the inhibition of penile NO synthesis (Maas et al., 2002).
In fact, also L-arginine ⁄ADMA ratio in ED AR is signifi-
cantly lower than in ED NON-AR and controls. Further-
more, the increased SDMA competes with the L-arginine
entrance in the cells reducing the availability for NO syn-
thesis. ED, but only ED AR, may be the earliest manifes-
tation of a generalized vascular disease and only these
patients may be at risk of later developing CAD.
Recently, Elesber (Elesber et al., 2006) and Aktoz (Ak-
toz et al., 2010), comparing plasma ADMA concentration
and severity of ED and coronary artery disease, demon-
strated a significantly negative correlation between IIEF
score and ADMA levels, but none of the two studies split
the ED patients in relation to the different aetiology (AR
and NON-AR) according to the penile echo-colour-
Doppler after intracavernous injection of prostaglandin
E1. Our results showed a significantly negative correlation
between serum ADMA levels and IIEF score but only in
ED AR subgroup confirming the role of ADMA in ED
but only in those patients with ED of arteriogenic origin.
Chen et al. (Chen et al., 1999) reported significant
improvement in sexual function when ED patients char-
acterized by relative L-arginine deficiency (L-argi-
nine ⁄ADMA elevated), were treated with L-arginine
supplementation in combination with phosphodiesterase
type s (PDE-5) inhibitors. Quite recently, the oral supple-
mentation with arginine or citrulline (which escapes
intestinal or liver metabolism, enters the kidneys and is
rapidly converted into L-arginine) has been also proposed
to patients with mild ED and in heart failure (Cormio et
al., 2011; Orozco-Gutierrez et al., 2010), thus providing
the rationale for oral L-citrulline supplementation as a
donor for the L-arginine ⁄NO pathway in patients with
endothelial dysfunction. From the results of our study, we
can speculate that only a subgroup of ED patients, ED
AR with elevated ADMA, might benefit from L-arginine
or L-citrulline supplementation. For this reason, we think
advisable to recognize between the ED patients those with
arteriogenic aetiology.
In conclusion, NO pathway is of critical importance in
the physiological regulation of erection. Elevated endoge-
nous NOS inhibitor, like ADMA, not balanced by and
increased L-arginine concentration, contributes to NO
deficiency, leading impaired NO-mediated relaxation in
the lower urinary tracts and corpus cavernosum. More-
over, our observations could be also interpreted as
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evidence for a reduced systemic availability of L-arginine
in men with ED; but only in men with ED AR, ADMA
appears to be preferentially elevated and both L-argi-
nine ⁄ADMA ratio and L-arginine ⁄ SDMA ratio decreased;
thus, confirming in this subgroup the diagnosis of vascu-
lar origin of ED obtained with the penile echo-colour-
Doppler procedure. Nevertheless, the levels of ADMA and
of L-arginine ⁄ADMA are not sufficiently different to
accurately discern between AR and NON-AR patients.
Probably because the precise aetiology of NON-AR ED
can be difficult to elucidate and may be because of a
combination of organic as well as psychological factors.
Taken together with the relatively small number of sam-
ples in this study, this may account for the fact that levels
of ADMA and L-arginine ⁄ADMA, even though a statisti-
cally significant difference was shown between AR and
NON-AR patients, can not accurately differentiate a single
patient presenting with ED in clinical setting.
Additional studies are required to define the impor-
tance of ADMA in ED, but the results demonstrate that
future research should investigate separately AR from ED
NON-AR patients, because they belongs to different pop-
ulation and accordinges to severity of arteriogenic status
by using PSV values (Ioakeimidis et al., 2011). This will
increase understanding of the role of ADMA in the mech-
anisms that lead to ED and potentially provide therapeu-
tic targets.
Finally, our results point out the importance of the
determination of ADMA, SDMA and L-arginine concen-
tration that we suggest to insert in the list of the tests for
an early screening of ED patients.
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